Inflammatory factors in psoriasis patients, such as TNF-α, IL-6, IL-22, etc., in addition to causing skin lesions, also promote the occurrence of metabolic disorders and increase the risk of MetS. This evidence concerns the gene IL22 and metabolic syndrome.